Table 1.
Relationship between the expression of TRIM32 and clinicopathological features.
| Variables | Totalno.(%) | TRIM32low (n = 15) | TRIM32high (n = 31) | P value |
|---|---|---|---|---|
| Gender (n, %) | 0.766 | |||
| Male | 29 (63.0) | 9 (60.0) | 20 (64.5) | |
| Female | 17 (37.0) | 6 (40.0) | 11 (35.5) | |
| Age, years | 0.519 | |||
| Median (Range) | 48 (17-78) | 44 (17-65) | 50 (22-78) | |
| WBC count, *109/L | 0.246 | |||
| Median (Range) | 19.6 (1.7-169.0) | 14.75 (2.5-169) | 22.21 (1.68-159.16) | |
| Hemoglobin, g/L | 0.089 | |||
| Median (Range) | 72 (42-128) | 90 (50-117) | 70 (42-128) | |
| Platelet count, *109/L | 0.888 | |||
| Median (Range) | 50 (4-312) | 46 (8-250) | 51 (4-312) | |
| Blast in bone marrow (%) | 0.605 | |||
| <50 | 16 (34.8) | 6 (40.0) | 10 (32.3) | |
| ≥50 | 30 (65.2) | 9 (60.0) | 21 (67.7) | |
| Karyotype | 0.880 | |||
| Favorable | 4 (8.7) | 1 (6.7) | 3 (9.7) | |
| Intermediate | 38 (82.6) | 13 (86.7) | 25 (80.6) | |
| Adverse | 4 (8.7) | 1 (6.7) | 3 (9.7) | |
| Fusiongenes | 0.419 | |||
| Favorable | 7 (15.2) | 2 (13.3) | 5 (16.1) | |
| Intermediate | 37 (80.4) | 13 (86.7) | 24 (77.4) | |
| Adverse | 2 (4.3) | 0 (0.0) | 2 (6.5) | |
| 2017 ELN | 0.062 | |||
| Favorable | 3 (6.5) | 0 (0.0) | 3 (9.7) | |
| Intermediate | 27 (58.7) | 12 (80.0) | 15 (48.4) | |
| Adverse | 16 (34.8) | 3 (20.0) | 13 (41.9) | |
| CR1 | 0.005 | |||
| Yes | 14 (30.4) | 1 (6.7) | 13 (41.9) | |
| No | 25 (54.3) | 13 (86.7) | 12 (38.7) | |
| NA | 7 (15.2) | 1 (6.7) | 6 (19.4) | |
| Biallelic CEBPA Mut* | 10 (24.4) | 6 (42.9) | 4 (14.8) | 0.047 |
| DNMT3A Mut* | 11 (26.8) | 3 (21.4) | 8 (29.6) | 0.569 |
| NPM1 Mut* | 12 (29.3) | 5 (35.7) | 7 (25.9) | 0.514 |
| FLT3-ITD Mut* | 15 (36.6) | 5 (35.7) | 10 (37.0) | 0.934 |
| FLT3-TKD Mut* | 3 (7.3) | 0 (0.0) | 3 (11.1) | 0.105 |
| TET2 Mut* | 7 (17.1) | 3 (21.4) | 4 (14.8) | 0.598 |
| EZH2 Mut* | 3 (7.3) | 2 (14.3) | 1 (3.7) | 0.232 |
| NRAS Mut* | 9 (22.0) | 2 (14.3) | 7 (25.9) | 0.380 |
| PTPN11 Mut* | 5 (12.2) | 0 (0.0) | 5 (18.5) | 0.033 |
| RUNX1 Mut* | 4 (9.8) | 1 (7.1) | 3 (11.1) | 0.678 |
| KIT Mut* | 3 (7.3) | 1 (7.1) | 2 (7.4) | 0.975 |
| IDH1 Mut* | 3 (7.3) | 1 (7.1) | 2 (7.4) | 0.975 |
| IDH2 Mut* | 3 (7.3) | 2 (14.3) | 1 (3.7) | 0.232 |
CR1, complete remission (CR) after first induction therapy. A P value of less than 0.05 is indicated in italics and bold. * Next generation sequencing data is missing from 5 patients. NA, notavailable.